TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer
- PMID: 16585160
- DOI: 10.1158/0008-5472.CAN-06-0168
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer
Abstract
Although common in hematologic and mesenchymal malignancies, recurrent gene fusions have not been well characterized in epithelial carcinomas. Recently, using a novel bioinformatic approach, we identified recurrent gene fusions between TMPRSS2 and the ETS family members ERG or ETV1 in the majority of prostate cancers. Here, we interrogated the expression of all ETS family members in prostate cancer profiling studies and identified marked overexpression of ETV4 in 2 of 98 cases. In one such case, we confirmed the overexpression of ETV4 using quantitative PCR, and by rapid amplification of cDNA ends, quantitative PCR, and fluorescence in situ hybridization, we show that the TMPRSS2 (21q22) and ETV4 (17q21) loci are fused in this case. This result defines a third molecular subtype of prostate cancer and supports the hypothesis that dysregulation of ETS family members through fusions with TMRPSS2 may be an initiating event in prostate cancer development.
Similar articles
-
Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.Cancer Res. 2008 Jan 1;68(1):73-80. doi: 10.1158/0008-5472.CAN-07-5352. Cancer Res. 2008. PMID: 18172298
-
Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.Oncol Rep. 2007 May;17(5):1033-6. Oncol Rep. 2007. PMID: 17390040
-
Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer.Cancer Res. 2008 May 1;68(9):3094-8. doi: 10.1158/0008-5472.CAN-08-0198. Cancer Res. 2008. PMID: 18451133
-
The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications.Adv Anat Pathol. 2009 May;16(3):145-53. doi: 10.1097/PAP.0b013e3181a12da7. Adv Anat Pathol. 2009. PMID: 19395877 Review.
-
Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management.Adv Anat Pathol. 2013 Mar;20(2):117-24. doi: 10.1097/PAP.0b013e3182862ac5. Adv Anat Pathol. 2013. PMID: 23399797 Review.
Cited by
-
Advances in sequencing and omics studies in prostate cancer: unveiling molecular pathogenesis and clinical applications.Front Oncol. 2024 May 10;14:1355551. doi: 10.3389/fonc.2024.1355551. eCollection 2024. Front Oncol. 2024. PMID: 38800374 Free PMC article.
-
Systematic review and integrated analysis of prognostic gene signatures for prostate cancer patients.Discov Oncol. 2023 Dec 19;14(1):234. doi: 10.1007/s12672-023-00847-4. Discov Oncol. 2023. PMID: 38112859 Free PMC article.
-
Biomarkers for Prostate Cancer: From Diagnosis to Treatment.Diagnostics (Basel). 2023 Oct 31;13(21):3350. doi: 10.3390/diagnostics13213350. Diagnostics (Basel). 2023. PMID: 37958246 Free PMC article. Review.
-
RSPO2 as Wnt signaling enabler: Important roles in cancer development and therapeutic opportunities.Genes Dis. 2023 Apr 19;11(2):788-806. doi: 10.1016/j.gendis.2023.01.013. eCollection 2024 Mar. Genes Dis. 2023. PMID: 37692504 Free PMC article. Review.
-
Unravelling the Role of P300 and TMPRSS2 in Prostate Cancer: A Literature Review.Int J Mol Sci. 2023 Jul 11;24(14):11299. doi: 10.3390/ijms241411299. Int J Mol Sci. 2023. PMID: 37511059 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical